A Game-Changer for Multi-Food Allergies? Omalizumab Matches Oral Immunotherapy's Long-Term Success - With Far Less Hassle
For patients and families dealing with multiple food allergies, new follow-up data from the landmark OUtMATCH trial bring encouraging news: the biologic medication omalizumab (Xolair) performs just as well as multi-food oral immunotherapy (mOIT).
In this analysis of 80–81 participants who completed initial treatment for 1–3 food allergies, both groups transitioned to real-world dietary consumption plans. Success meant regularly tolerating at least 300 mg per day of each allergen - roughly a meaningful, protective amount in accidental exposures or intentional inclusion.
Daily diary tracking at 3 and 6 months showed nearly identical outcomes: mOIT hit about 77% success at 3 months and 65% at 6 months, while omalizumab reached 66% and 63% (differences not statistically significant). Clinician reviews through a full 12 months confirmed the same pattern across foods, including peanut - no meaningful gaps between the approaches.
Safety remained comparable, with very few serious reactions (rare anaphylaxis) and only one new EoE case after omalizumab.
These Stage 3 results build on earlier OUtMATCH findings, where omalizumab proved superior to mOIT during active treatment due to fewer side effects and dropouts. Now, even after treatment stops, the benefits hold up similarly - suggesting omalizumab could be a game-changing, lower-burden option for multi-food desensitization.
Food allergy management is evolving fast - and for those with multiple triggers, this could open doors to more freedom and peace of mind. Always discuss with your allergist, as individual responses vary.